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Summary 
Peptide analogues of disease-associated epitopes were studied for inhibition of experimental allergic 
encephalomyelitis (EAE)  and adjuvant arthritis (AA) in Lewis rats.  EAE-  and AA-associated 
analogues were selected as competitors because of their in vitro inhibitory activity on proliferation 
of encephalitogenic and arthritogenic T  cells. Although the EAE-associated  competitor had a 
superior major histocompatibility complex (MHC) binding af~nity, the AA-associated competitor 
was a better inhibitor of the in vitro proliferation of arthritogenic T cells. Furthermore, although 
in vivo EAE was inhibited by both competitors, AA was only inhibited by the AA-associated 
competitor. Remarkably, in contrast to what was expected of a regular MHC competitor peptide, 
the AA-associated peptide analogue also prevented AA upon immunization before disease induction 
and appeared to induce T  cell responses  that crossreacted with the original disease-associated 
epitope. Therefore, it is concluded that antigen-specific  regulatory mechanisms were involved 
in synergy with MHC competition. The integration of both qualities into a single "competitor- 
modulator" analogue peptide may lead to the development of novel, more effective, disease-specific 
immunomodulatory peptides. 
C 
D4  helper T  cells are activated  upon recognition of 
antigen, provided the antigen is processed and its pep- 
tides are presented by cells expressing the proper MHC class 
II products (1-3). Competition between various peptides for 
binding to the same MHC molecule already has been demon- 
strated to occur not only in vitro but also in vivo (4-9). These 
findings, added to the fact that predisposition to most an- 
toimmune diseases occurs in association with particular MHC 
molecules (10), have prompted several groups to investigate 
the possibility of inhibiting the formation of the trimolecular 
complex formed by MHC, peptide, and TCR in order to 
develop a new strategy of immunological  intervention in au- 
toimmunity. One of the best studied experimental animal 
models is the experimental allergic encephalomyelitis (EAE) 1 
model. EAE is a CD4 + T cell-mediated disease (11-13) that 
can be induced by immunization with myelin basic protein 
(MBP) or peptides derived from MBP. Both in mice and rats, 
1 Abbreviations used in thispaper: AA, adjuvant arthritis; EAE, experimental 
allergic encephalomyelitis; MBP, myelin basic protein; SMPS, simultaneous 
multiple  peptide  synthesis. 
CD4 + MBP-specific helper T cell clones have been isolated 
that transfer the disease into naive recipient animals (11, 13). 
Coadministration of anti-MHC class II antibodies has pre- 
vented the induction of EAE in mice by blocking MHC rec- 
ognition of potentially encephalitogenic T  helper cells (14, 
15). Based on these findings, several groups have searched 
for peptides that could inhibit, by competition for MHC class 
II binding, the stimulus that is turning on the dangerous 
anti-self T cell responses. First reports dealing with this pep- 
tide immunotherapy approach have indicated it to be suc- 
cessful in the EAE model in mice. Coimmunization of nonen- 
cephalitogenic peptide analogues,  designed on the basis of 
known encephalitogenic MBP T cell epitopes, together with 
MBP or MBP peptides reduced the clinical signs of EAE (16, 
17). However, as also suggested by Janeway (18), because of 
the dose structural relationships between inhibitors and en- 
cephalitogenic peptides, one could question whether MHC 
blockade was the sole mechanism of the successful immuno- 
logical intervention in the disease process, or that immune 
responses elicited or suppressed by the analogue peptides them- 
selves were interfering with the anti-self immune responses. 
In the present study, we asked ourselves whether the ap- 
proach of blocking peptides would work in more complex 
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by an unnatural exposure to a well-defined self-peptide. Fur- 
thermore,  when peptide immunotherapy  is only based on 
competition for MHC binding,  it should be possible to use 
the same competitor peptide in different experimental models, 
provided that in these models the same MHC restriction ele- 
ments are involved. To study these questions we selected two 
experimental models in rats, the adjuvant arthritis (AA) model 
and the peptide-induced EAE model. The AA model, an ex- 
perimental model for rheumatoid arthritis, is relatively com- 
plex compared with the peptide-induced EAE model, because 
the disease is not induced by an immunization with a defined 
self-antigen but by immunization with whole Mycobacterium 
tuberculosis (Mt), comprising many distinct  antigens  (19). How- 
ever, among T cell lines obtained from Mr-immunized Lewis 
rats,  solar exclusively lines or clones with specificity for the 
180-188 amino acid sequence of the mycobacterial 65-kD heat- 
shock protein  (M-65  180-188)  have been shown to be ar- 
thritogenic in vivo (20-23). In the EAE model in Lewis rats, 
encephalitogenic T  cells recognizing the 72-89 amino acid 
sequence of guinea pig MBP (MBP 72-89) dominate the im- 
mune response (24).  Analysis of the MHC restriction  ele- 
ment of an arthritogenic T  cell clone (A2b), responding to 
the mycobacterial 180-188 epitope, and an encephalitogenic 
T cell line (Zla), responding to the MBP 72-85 epitope, re- 
vealed that both were MHC class II RT1 B L (I-A) restricted 
(25). Based on these observations, our aim was to design com- 
petitor peptides that could inhibit  in vivo, by competition 
at the level of MHC binding,  triggering  of autoaggressive 
T  cells in both models.  For the design of competitor pep- 
tides we used both the 180-188 amino acid sequence of the 
mycobacterial 65-kD protein,  and the 72-85 amino acid se- 
quence of MBP. First, we selected in vitro single alanine-sub- 
stituted analogues of peptide 180-188 and MBP 72-85 (pep- 
tide 1020) that were not stimulatory for, respectively, clone 
A2b and Zla, and that showed in vitro an efficient inhibition 
of the antigen-induced proliferative responses of both T cell 
clones. Coimmunization of both the AA- and EAE-associated 
competitor peptides together with the encephalitogenic MBP 
72-85 peptide (peptide 1020) resulted in a strong inhibition 
of EAE. However, in the AA model, only coimmunization 
of  the  AA-associated  competitor  peptide  together  with 
Mt/IFA resulted in strong disease inhibition, while, although 
the EAE-associated competitor peptide had a higher binding 
affinity for MHC class II molecules, no significant  disease 
inhibitory activity of the EAE-associated competitor peptide 
was seen. In animals immunized with the AA-associated com- 
petitor peptide, draining lymph node lymphocytes showed 
proliferative responses against the competitor peptide itself, 
which coincided with raised responses to the original pep- 
tide 180-188. Preimmunization with the AA-associated com- 
petitor peptide before disease induction  inhibited  develop- 
ment of AA, while the induction of EAE was not affected. 
This study shows that besides MHC blockade, as shown in 
the peptide-induced EAE model, analogues of a disease-related 
epitope may elicit an additional  antigen-specific inhibitory 
mechanism. 
Materials  and Methods 
Rats.  Male inbred Lewis rats, 160-190 g (6-8 wk of age), were 
obtained  from  the  University  of  Limburg  (Maastricht,  The 
Netherlands). 
T Cell Lines.  The isolation, maintenance, and properties of the 
A2b helper T ceU clone have been described previously (21). Briefly, 
an arthritogenic  T cell clone, A2, reactive to Mt, was first isolated 
from draining lymph nodes of a Lewis rat immunized with Mt in 
IFA (20). Subcloning of the A2 line revealed the presence of an 
arthritogenic  T  cell clone, A2b, which recognized  the 180-188 
amino acid sequence of the mycobacterial hsp65 (23). The isola- 
tion, maintenance, and properties of the encephalitogenic Zla helper 
T cell line have been described previously (26). Briefly, T cell line 
Zla reactive to the 72-85 amino acid sequence of guinea pig MBP 
was isolated from the draining lymph nodes of a Lewis rat 9 d after 
immunization  into each footpad with guinea pig MBP in CFA. 
The CD4 + T cell line ATL was isolated from the popliteal lymph 
node cells of a Lewis rat  10 d after footpad immunization  with 
100/~g peptide A183 in CFA. Subcloning of the ATL line revealed 
the presence of the ATL11 T cell clone specific for both peptide 
180-188 and A183. T cell lines were cyclically  restimulated in vitro 
for 3 or 4 d with irradiated (3,000 rad) thymocytes as APCs and 
10/xg/ml heat-killed Mt for clone A2b, 10/~g/ml MBP for T cell 
line Zla, or 10 #g/ml peptide A183 for clone ATL11, and propagated 
for 6 or 7 d in IMDM (Gibco Laboratories, Grand Island, NY), 
supplemented with 10% FCS, 10% EL-4 supernatant (Ib2 source), 
2 mM glutamine,  2-ME, antibiotics, and 1% nonessential amino 
acids. 
Antigens.  The single alanine-substituted  peptide analogues of 
peptide 180-188, the 180-188 amino acid sequence of the mycobac- 
teria165-kD protein (M-65 180-188), and ofpeptide 1020, the 72-85 
amino acid sequence of guinea pig MBP (MBP 72-85), were pre- 
pared by automated simultaneous multiple peptide synthesis (SMPS). 
The SMPS set-up was developed using a standard autosampler (221; 
Gilson Co., Inc., Worthington, OH) as described elsewhere (27). 
Shortly, for the concurrent synthesis of 30 peptides, standard Fmoc 
chemistry with Pfp-activated  amino acids (Dhbt for serine and threo- 
nine) in a sixfold molar excess  and Hobt as catalyst were employed. 
Peptides were obtained as COOH-terminal amides from 7.5 nag 
resin/peptide  (0.21 meq/g,  PAL TM resin; Milligen, Etten-Leur, 
the Netherlands).  Large quantities  of synthetic  peptide  180-188 
(M-65 180-188),  TFGI.QLELT, peptide  A183 (M-65  180-188, 
Leu183-,.Ala),  TFGAQLELT, peptide  A184 (M-65  180-188, 
Gln184-,-Ala), TFGLALELT, peptide 1020 (MBP 72-85). QKSQ- 
RSQDENPV, peptide 1028 (MBP 72-85, Asp81-,-Ala), QKSQRS- 
QAENPV, and peptide 1029 (MBP 72-85 Glu82~Ala), QKSQRS- 
QDANPV were synthesized by standard solid phase Fmoc chemistry 
(23, 28). The activities of in vitro defined noninhibitory  and in- 
hibitory peptides synthesized by the SMPS method were confirmed 
with the alanine-substituted peptides (A184, 1029 and A183, 1028) 
prepared by conventional  solid phase synthesis. Heat-killed  Mt 
H37Ra was derived from Difco Laboratories (Detroit,  MI). The 
65-kD M. boris BCG recombinant protein (M-65) was cloned and 
purified as described previously (23, 29). 
Lymphocyte Proliferation Assay.  Proliferative responses of the T 
cell lines were measured in flat-bottomed microtiter plates in tripli- 
cate cultures (21). Each well contained 2  x  104 T cells, irradiated 
(3,000 tad)  syngeneic thymocytes (106 cells/well) as APCs,  and 
various amounts  of antigens in 0.2 ml IMDM (Gibco Laborato- 
ries, Grand Island, NY) supplemented with 2% rat serum, gluta- 
mine, 2-ME, and antibiotics. Polyclonal responses of freshly iso- 
lated lymphocytes from  draining  lymph  nodes or spleens were 
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plemented  with 10% FCS (Seralab, Sussex, England)  instead of 
2% rat serum. The cells were cultured for 3 d and pulsed for 18 h 
with [3H]thymidine. Cells were harvested on fiberglass filters, and 
[3H]thymidine incorporation  was measured. 
Competitive Proliferation  Assay.  To assess the capacity of non- 
stimulatory substituted peptides to inhibit antigen-induced prolifer- 
ation of clone A2b or Zla, varying concentrations  of competitor 
peptides were added to the culture containing  T cells and irradi- 
ated thymocytes 2 h before the addition of a suboptimal dose of 
the stimulatory antigens. The T lymphocyte proliferation assay  was 
performed  as mentioned  above. 
MHC Binding Assay.  The MHC-peptide binding studies were 
performed using a direct binding  assay (30). Briefly, Rat RT1 B  r 
molecules were affinity purified from cell lysates of the Con A-ac- 
tivated MHC class II-positive Z1A T cell line using the mAb Ox6 
coupled to Sepharose-4B beads. Peptide 1020 (MBP 72-85)  was 
biotinylated with a twofold molar excess of  N-hydroxy-succinimide 
(NHS)-LC-Biotin  (Pierce Chemical Co., Rockford, IL). For com- 
petition  studies purified MHC class II molecules (2/zM) were in- 
cubated with 100 nM of biotinylated peptide 1020 and a dose range 
of 0-100/~M nonlabeled competitor peptides for 48 h at room tem- 
perature in the presence of a protease inhibitor  mix.  The MHC- 
peptide mixtures were analyzed by SDS-PAGE under nonreducing 
conditions. The proteins were then blotted onto nitrocellulose. After 
blocking the blot was incubated with biotinylated streptavidin-HRP 
complexes (Amersham Corp.,  Arlington  Heights,  IL). Detection 
of the presence of labeled peptide was by enhanced chemilumines- 
cence using the Western blot ECL kit (Amersham Corp.). Exposure 
was overnight  on Hyperfilm-ECL  (Amersham Corp.). 
Induction and Clinical Evaluation of AA.  AA was induced by 
inoculation  of 0.1  ml  of a  1:1  emulsion  of heat-killed  Mt  (5 
mg/ml)/IFA and PBS intracutaneously  at the base of the tail. All 
rats were examined daily, in a blind set-up, for clinical signs of ar- 
thritis.  The severity of arthritis  was scored by grading each paw 
from 0 to 4 based on erythema,  swelling, and deformity  of the 
joints. The highest achievable score was 16 (31). Statistical analysis 
was performed with the Student's t test. The in vivo effect of pep- 
tides A183, A184, 1028, and 1029 was investigated by coimmuni- 
zation  at the base of the tail of 0.1 ml of a 1:1 emulsion of Mt 
(5 mg/ml)/IFA together with 250/xg peptide/PBS. 
Induction and Clinical  Evaluation of EAE.  EAE was induced by 
injecting 0.05 ml of a 1:1 emulsion of the encephalitogenic peptide 
1020 (72-85  amino  acid sequence of guinea  pig  MBP)/PBS (1 
mg/ml) and CFA (4 mg/ml Mt) in each hind  footpad.  Clinical 
signs of EAE were monitored daily on a scale of 0 to 4: 0, no signs; 
0.5, weight loss; 1, limp tail; 2, hind leg weakness; 3, paraplegia; 
4, paraplegia with forelimb weakness, moribund condition.  The 
in vivo effect of peptides 1028, 1029, and A183 was investigated 
by  adding  these  peptides  (500  #g/animal)  to  the  1020/CFA 
emulsion. 
Immunization with Peptide A183 before l~'sease Induction.  Rats 
were immunized,  7 d before disease induction,  at the base of the 
tail in case of the EAE model and in the hind footpads in case of 
the AA model, with 100 #1 of a 1:1 emulsion of peptide A183/PBS 
(1  mg/ml)  or  with  dimethyl-dioctadecylammonium  bromide 
(DDA)/PBS (10 mg/ml).  In the AA model,  the disease was in- 
duced by intracutaneous injection at the base of the tail of 100/~1 
Mt/IFA (5 mg/ml). In the EAE model, the disease was induced 
by subcutaneous injection in both hind footpads of 50/~1 of a 1:1 
emulsion ofpeptide 1020/PBS (1 mg/ml) and CFA (Mt, 4 mg/ml). 
To circumvent the use of a mycobacteria-containing adjuvant, DDA 
was used as an alternative adjuvant,  as described by Snippe and 
Kraaieveld (32).  DDA was obtained  from Eastman  Kodak Co. 
(Rochester, NY). 
Results 
Identification of Nonstimulatory Alanine.substituted Peptide An- 
alogues.  For the design of competitor peptides based on the 
two disease-associated T cell epitopes, the 180-188 amino acid 
sequence of the mycobacteria165-kD protein (M-65 180-188) 
and the 72-85 amino acid sequence of guinea pig MBP (MBP 
72-85),  we first analyzed which residues within  these epi- 
topes were essential for stimulation  of, respectively, T  cell 
clone A2b and T cell line Zla. Single amino acid-substituted 
analogues of both T  cell epitopes were generated in which 
every residue was replaced by an alanine residue. Proliferative 
responses of T cell clone A2b and T cell line Zla in the pres- 
ence of the substituted peptide analogues were determined. 
As can be seen in Fig.  1 A, T  cell clone A2b responded in 
addition to the original peptide 180-188, only to the alanine- 
substituted peptide analogues A187 and A188. Fig. 1 B shows 
that T cell line Zla responded not only to the original MBP 
peptide 1020 (MBP 72-85), but also to the alanine-substituted 
peptide analogues 1021, 1024, 1026, 1030, and 1032, whereas 
a slight  response against  peptide  1031 was seen. 
Competitive Inhibition of the Proliferative Response of Clone 
A2b by Nonstimulatory Substituted Peptides.  The analysis  of 
the  substituted  peptide  analogues  provided  us with  non- 
stimulatory peptides with unknown MHC binding charac- 
teristics. An indirect method for studying MHC binding is 
to investigate whether a nonstimulatory peptide can inhibit 
antigen-induced proliferative responses in vitro. Because both 
T cell clone A2b and T cell line Zla were MHC class II RT1 
B L (I-A) restricted (25), clone A2b was used to test the in- 
hibitory capacity of nonstimnlatory 180-188 (M-65)- and 1020 
(MBP 72-85)-derived analogue peptides. As can be seen from 
Fig. 2 A, addition of peptide analogue A181 (M-65 180-188, 
Phe181---~Ala) or A183 (M-65 180-188, Leu183--~Ala) induced 
a concentration-dependent inhibition of the proliferative re- 
sponse against peptide 180-188 (0.5 #g/ml).  Peptide A182 
(M-65 180-188, Gly182-*Ala) showed only a slight concen- 
tration-dependent inhibition, while the alanine  substitutions 
at positions 180, 184, 185, and 186 within the 180-188 pep- 
tide failed to inhibit the proliferative  response induced by pep- 
tide 180-188. Of the 1020 (MBP 72-85) analogues, only ad- 
dition of peptide 1028 (MBP72-85, Asp81---- Ala), induced 
a strong concentration-dependent  inhibition  of the peptide 
180-188-induced proliferation  of clone A2b (Fig.  2 B). 
Comparison of the Inhibitory Activity of  Peptide A183 and 1028 
on T Cell Proliferation.  We selected the analogue of peptide 
180-188 (M-65 180-188), peptide A183 (Leu183--Ala), and 
the analogue of peptide  1020 (MBP 72-85),  peptide  1028 
(Asp81-~Ala), to compare their efficacy in inhibiting prolifer- 
ation of both clones A2b and Zla. Fig. 3 A  shows that pep- 
tide  A183  inhibited  the  proliferation  of clone  A2b  more 
efficiently than the nonrelated peptide 1028.  However, Fig. 
3 B shows that the peptide 1020-induced proliferation of Zla 
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Figure 1.  Proliferative responses 
([3H] thymidine  incorporation)  of 
clone A2b and T cell line Zla to, 
respectively, peptide  180-188 and 
peptide  1020 single  alanine-sub- 
stituted analogue peptides. The re- 
sponses of T  cell done  A2b are 
shown  in  the  presence  of single 
alanine*substituted  peptide  ana- 
logues  of peptide  180-188  (2-3 
#g/ml) (A). The responses ofT cell 
line Zla are shown in the presence 
of single alanine~substituted peptide 
analogues of peptide  1020 (30-50 
#g/ml) (B). Data are ~pressed as 
stimulation  indices. Sl, mean cpm 
of triplicate samples in the presence 
of antigen/mean cpm of triplicate 
samples in the absence of antigen. 
was inhibited more efficiently by the analogue Peptide 1028 
compared with the nonrelated Peptide A183. 
MHC Binding Affinity of the Competitor Peptides.  Because 
the proliferative responses of both clones A2b and Zla, were 
inhibited most efficiently  by their homologous epitope-related 
Peptide analogues, it is possible that this inhibition was not 
merely based on competition at the level of Peptide-MHC 
binding, but that also antigen-specific mechanisms at the level 
of the TCK were involved. To determine the MHC binding 
affinities of both competitor peptides and to discriminate MHC 
binding  from  TCR-specific  effects, we performed direct 
Peptide-MHC binding experiments  on isolated MHC class 
II molecules.  Purified  MHC class II molecules  (RT1  B  L) 
were incubated with the biotinylated marker peptide 1020 
together with various concentrations of the nonlabeled com- 
petitor Peptides A183 or 1028 for 48 h. Binding of the la- 
beled marker Peptide was analyzed by nonreducing SDS-PAGE 
followed by blotting. Biotinylated Peptide-MHC binding was 
detected by chemoluminescence. This method enables com- 
petition studies in which the relative affinity of a given Pep- 
tide as compared with the marker Peptide can be assessed 
in a semi-quantitative way (30). Fig. 4 A shows the competi- 
tive inhibition of MHC binding of biotinylated Peptide 1020 
by increasing concentrations of Peptide 1028. At 40-fold molar 
excess of competitor 1028, the binding had decreased by 
,,o90%. The competitive inhibition by peptide A183 (Fig. 
4 B) appeared to be less efficient, at 40-fold molar excess the 
binding  has  decreased by  ,o50%.  Therefore,  the  MHC 
binding affinity of the EAE-associated analogue Peptide 1028 
is higher than the binding affinity of Peptide A183. The fact 
that, despite the lower MHC binding affinity of peptide A183, 
the proliferation of clone A2b was inhibited more efficiently 
by Peptide A183 compared with Peptide 1028 (Fig. 3 A) is 
likely due to inhibitory mechanisms other than MHC com- 
petition. 
EAE Blocking Activity of Peptides A183 and 1028.  Because 
both Peptides A183 and 1028 inhibited the antigen-induced 
proliferation  of T  cell clone A2b and T  cell line Zla, and 
because both cells were critical for disease development  of 
AA or EAE, respectively, we subsequently studied the ability 
to use Peptides A183 and 1028 as competitor Peptides during 
disease induction in both models. Peptides A184 and 1029 
were selected as noncompetitive control Peptides (See Fig. 
2, A  and B). EAE was induced with the encephalitogenic 
Peptide 1020 (MBP 72-85)  (50 #g/rat) emulsified in CFA. 
Coimmunization with Peptide 1028 (500 #g/rat) resulted in 
a complete inhibition of EAE, while coimmunization of pep- 
tide A183 (500/~g/rat) resulted in almost complete inhibi- 
tion of EAE (Table 1). Only two of eight animals coimmunized 
with A183 showed dinical signs of EAE, and the maximal 
score of these two animals was only 0.5 (weight loss without 
any signs of paralysis). In contrast, all animals coimmunized 
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Figure 2.  Competition for an- 
tigen  presentation  between  non- 
stimulatory single alanine-substi- 
tuted peptide analogues and peptide 
180-188.  Nonstimulatory alanine- 
substituted  peptide  analogues  of 
peptide 180-188  (A) and peptide 
1020 (B) were preincubated with 
APCs and A2b T  cells 2 h before 
the addition of the stimuhtory pep- 
tide  180-188.  Competition  was 
evaluated in a proliferation assay by 
determining the reduction of pro- 
liferation in the presence of a varying 
concentration of competitor pep- 
tides and a suboptimal concentra- 
tion ofpeptide 180-188 (0.5 #g/ml). 
The background value in the test 
was (A) 211 cpm and (/3) 164 cpm. 
Data are expressed as the mean cpm 
of triplicate cultures. 
Table  1.  Coimraunization  of 1028 or A183 Inhibits Peptide-induced EAE 
Immunization*  Incidence*  Day of onsets  Durationll  Maximal severityl 
1020  (50  #g)  +  PBS 
1020  (50 #g)  +  1028  (500  #g) 
1020 (50 ~,g)  +  A183  (5o0 ~,g) 
1020  (50/~g)  +  1029  (500/~g) 
8/8  12.9  _+  1.4  5.8  _+  1.7  2.0  _+  1.1 
0/8  -  -  - 
2/8  13.0  +  0  1  +  0  0.1  _+  0.2 
8/8  11.8  _+  1.0  5.5  +  0.9  2.6  +  0.8 
* EAE was induced by subcutaneous  injection of 1020 (50/~g)  +  CFA (Mr 400/~g) emulsified with PBS,  1028 (500 #g), A183 (500 #g), or 1029 
(500  #g).  Rats were observed daily and graded on a four-point scale. 
* Number with disease/number tested. 
S Average day of disease onset of those animals  that developed disease ( _+ SD). 
II Average duration of the disease in days of those animals  that developed disease. 
￿82  Value represents the mean of the maximum EAE score for each experimental group. 
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Figure 3.  Inhibitory activity of peptides A183 and 1028 on T  cell proliferation.  Competition assays were performed  as described for Fig. 2. The 
inhibitory  activity of peptides A183 and 1028 are expressed as percent inhibition  of the peptide 180-188 (0.49 #M)-induced  proliferation of clone A2b 
(A) or the peptide  1020 (3.55/xM)-induced  proliferation  of Zla (B). 
with control peptide 1029 developed severe EAE, comparable 
to the control group immunized with peptide 1020/PBS in 
CFA (Table 1).  At day 35  after  EAE induction, popliteal 
lymphnode  cells of rats immunized  with the encephalitogenic 
peptide 1020/CFA together with either PBS, peptide A183, 
peptide 1028, or peptide 1029 were isolated and assessed for 
their antigen specificity in a proliferation assay. Table 2 shows 
in a representative experiment polyclonal T cell responses of 
animals coimmunized with the competitor peptides 1028 or 
A183, in which, as compared with the control groups im- 
munized with PBS or peptide 1029, decreased  responses against 
the encephalitogenic peptide 1020 were seen. These results 
were compatible with in vivo competitive inhibition of the 
priming of a T cell response against the encephalitogenic pep- 
tide 1020 and subsequent prevention of EAE development. 
Inhibitory Activity of Peptides A183 and 1028 in  the AA 
Model  However, the results of the coimmunization  experi- 
ments in the AA model were not compatible with such a 
competitive inhibition mechanism. Arthritis induction with 
Mt/IFA in the presence of the strongest MHC binding com- 
petitor peptide, peptide 1028 (MBP 72-85,  AspS1--~Ala), 
showed no significant disease inhibition as compared to the 
control groups  (Table 3).  In  contrast,  the weaker  MHC 
binding but  AA-related  competitor  analogue  of peptide 
180-188  (M-65  180-188),  peptide A183 (Leu183-~Ala),  re- 
duced  upon  coimmunization with  Mt/IFA  the  arthritis 
severity and incidence very effidently (Fig. 5). No significant 
effect on disease severity was seen after coimmunization  with 
control peptide A184 (Fig. 5). At day 43 after AA induction, 
when the clinical signs of arthritis in the affected groups had 
subsided, inguinal lymph node cells of animals immunized 
with Mt/IFA together with either PBS, peptide A183,  or 
peptide A184 were isolated and assessed for their antigen 
specificity in a proliferation assay. Table 4 shows the prolifer- 
ative responses of the inguinal lymph node cells of an animal 
of each experimental group. In contrast to the decreased poly- 
donal responses against the encephalitogenic peptide in animals 
coimmunized with the competitor peptides A183 or  1028 
in the peptide-induced EAE model (Table 2),  in the more 
complex AA model no inhibition of the responses  against 
Mt or the mycobacteria165-kD protein was observed in rats 
coimmunized with peptide A183 or 1028 (Table 4).  How- 
Figure 4.  Competitive inhibition of MHC binding 
of  biotinylated pepfide 1020  by peptides 1028 and A183. 
Competition studies for binding to 2/~M RT1 B  t 
MHC molecules were performed with different con- 
centrations  (0-100  ~M)  of nonlabded peptide  1028 
(MBP 72-85, Asp81-,,Ala) (A) or peptide A183 (M-65 
180--188, Leu183---~Ah)  (B), and 100 aM ofbiotinylated 
peptide 1020. The assays  were performed as described 
in Materials and Methods. 
672  Disease  Inhibition  by MHC Binding  Peptide Analogues Table  2.  Proliferative  Responses of Popliteal Lymph Node Cells 
at Day 35 after EAE Induction 
Rats immunized at day 0  with: 
Antigens  Dose  1020/PBS  1020/A183  1020/1028  1020/1029 
MBP 
1020 
1028 
1029 
A183 
Maximum 
EAE 
/~g/ml 
10  6.1  2.9  3.1  7.8 
25  11.0  3.3  5.3  8.2 
10  5.1  2.0  1.4  8.5 
25  11.4  2.0  1.5  12.1 
50  15.0  1.9  1.1  22.1 
50  1.8  1.2  10.0  6.0 
50  1.3  0.9  0.7  18.5 
50  1.5  34.0  1.3  0.9 
3  0  0  3 
Data are expressed as SI. For disease induction,  rats were immunized at 
day 0 with peptide 1020 (50/~g)  +  CFA (Mt 400/~g) emulsified with 
PBS, A183 (500 #g), 1028 (500/~g),  or 1029 (500/~g). 
ever, coimmunization of the immunogenic AA-related pep- 
tide A183 resulted not only in proliferative responses against 
peptide A183 itself, but, interestingly, also against peptide 
180-188, while in none of the other groups were responses 
against  peptide  180-188  observed.  From  these polyclonal 
proliferative responses it was not clear whether the same T 
cells that recognized peptide A183 also responded to peptide 
180-188. For this reason we generated a T cell clone, ATLll, 
against peptide A183. In agreement with our findings at the 
polyclonal level, this T  cell clone recognized, besides pep- 
tide A183, also the original peptide 180-188 (M-65 180-188) 
(Table 5). 
Table  3.  Coimmunization of 1028 or 1029 during Arthritis 
Induction with Mt 
Maximal 
Immunization"  Incidence*  Duration  s  severity  II 
Mt  +  PBS  6/6  7.8  _+  1.3  5.8  +  1.9 
Mt  +  1028  (250  #g)  4/5  6.8  _+  1.6  4  _+  1.6 
Mt  +  1029  (250 #g)  4/5  8.7  +  1.2  5.2  +  2.0 
* AA was induced by intracutaneous injection of CFA (Mr 5 mg/ml) 
emulsified with PBS, 1028 (250/~g),  or 1029 (250/~g). 
* Number with disease /  number tested. 
s Average duration of the disease  in days of those animals that developed 
disease. 
II Value represents the mean of the maximum AA score /  rat for each 
experimental group. 
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Figure 5.  Coimmunization of competitor peptide A183 during arthritis 
induction. Shown is the reduction of arthritis severity after disease  induc- 
tion with Mt in the presence of peptide A183. In the AA model, rats 
were coimmunized with Mt/IFA together with PBS (control group n = 
37); peptide A183, 250/~g/rat  (A183 group,,  =  18); or peptide A184, 
250/~g/rat (A184 group, n = 19). Rats were followed for disease  develop- 
ment from day 11 after immunization until day 43. The results shown 
are the mean arthritis scores of each group. SE is indicated by a bar. 
Preimmunization with Peptide A183 before Disease Induction 
Inhibited AA but Not EAE.  In the AA model coimmuniza- 
tion of the AA-related peptide A183 together with Mt/IFA 
inhibited the development of AA more efficiently than the 
stronger MHC  binding, but non-AA-related, peptide 1028 
(Table 3, Fig. 5). Furthermore, in the AA model no evidence 
for the inhibition of priming for critical disease-associated 
T  cell responses in vivo was seen after addition of the com- 
petitor peptides A183 or 1028 during disease induction with 
Mt/IFA (Table 4). However, animals coimmunized with pep- 
Table  4.  Proliferative  Responses of Inguinal Lymph Node Cells 
at Day 43 after Arthritis Induction 
Rats immunized at day 0  with: 
Antigens  Dose  Mt/- Mt/1028  Mt/1029  Mt/A183  Mt/A184 
/~g/ml 
Mt  10  36.9  36.0  30.6  36.5  23.5 
65  kD  25  3.0  5.4  6.1  4.4  5.1 
180-188  10  1.6  1.9  1.3  3.7  1.2 
25  1.3  1.7  1.2  3.9  1.4 
A183  10  1.5  1.8  1.4  3.8  1.2 
25  0.9  1.3  0.9  4.0  1.3 
A184  25  0.9  0.8  1.3  1.0  1.5 
1028  25  0.9  5.2  2.9  1.3  1.2 
1029  25  1.4  1.6  6.2  1.2  1.4 
Data are expressed as SI. For disease induction, rats were immunized at 
day 0 with Mt/IFA emulsified with PBS or 250/~g A183, A184, 1028, 
or 1029 in PBS. 
673  Wauben et al. Table 5.  Antigen Specificity of T  Cell Clone ATLll 
Antigens  Dose  Proliferative response 
#g/ml  cpm  +_  SD 
-  -  390  _+  10 
Con  A  2.5  87,995  _+  1,726 
180-188  1  82,720  _+  3,520 
10  123,194  _+  1,974 
A183  1  86,256  _+  1,552 
10  139,568  _+  2,318 
A184  1  508  _+  102 
10  362  _+  37 
tide A183 together with Mt/IFA showed, besides a response 
against peptide A183 itself, also an increased response against 
the original peptide  180-188, which plays a crucial role in 
AA development (Table 4). All these results suggested that 
in vivo peptide A183 probably interfered with the induction 
of AA by an antigen-specific mechanism rather than MHC 
blockade. However, to exclude MHC blockade and to study 
the antigen-specific protective mechanism of peptide A183, 
we tested whether preimmunization with peptide A183 in 
DDA, a nonmycobacteria-related adjuvant (32), at a relatively 
low dose (50 #g/rat compared with 250/~g/rat in the coim- 
munization experiments),  7 d before disease induction with 
Mt/IFA or peptide 1020 (MBP 72-85)/CFA, could influence 
the subsequent development of AA or EAE. First, before any 
macroscopical  signs  of  AA  were  observed  in  Mt/IFA- 
immunized animals, polyclonal T cell responses of animals 
preimmunized with PBS/DDA or peptide A183/DDA were 
assessed. Table 6 shows the results of one representative rat 
of each group.  No differences in the popliteal lymph node 
responses against Mt or the mycobacterial  65-kD protein were 
observed between the different animals, although it is clear 
that in the A183-preimmunized group responses against the 
original peptide 180-188 already were detected, while in the 
control group the response against peptide 180-188 was not 
yet detectable. Furthermore, as can be seen in Fig. 6, rats 
preimmunized with peptide A183 showed a significantly re- 
duced disease.severity  compared with the control group, which 
had received PBS/DDA at day  -7 (p <  0.05). In contrast, 
preimmunization at day -7 with peptide A183 did not in- 
terfere with the development of peptide-induced EAE (max- 
imal EAE score of 2.2  _+  1.2; data not shown). 
Discussion 
Of inbred rats, Lewis rats especially were found to be sus- 
ceptible to a number of experimental autoimmune diseases, 
such as EAE (12), AA (19), experimental autoimmune uveo- 
retinitis (EAU) (33), etc. Therefore, the development of com- 
petitor peptides, specific for Lewis MHC class II molecules, 
would enable the study of such peptides in different autoim- 
Table 6.  Proliferative  Responses of Popliteal Lymph Node Cells 
at Day 10 after Arthritis Induction 
Rats immunized with: 
Day-7 DDA/PBS  Day-7  DDA/A183 
Antigens  Dose  Day 0 Mt/IFA  Day 0 Mt/IFA 
#g/ml 
Mt  10  15.1  18.6 
65  kD  10  5.1  5.1 
50  7.9  7.0 
180-188  10  1.4  3.8 
50  1.6  3.9 
A183  10  1.1  3.5 
50  0.8  4.3 
A184  10  0.7  1.2 
50  0.9  1.4 
Data are expressed  as SI. Rats were immunized in the hind footpads at 
day  -  7 with PBS/DDA or 50 #g A183/DDA. Arthritis was induced 
by tail immunization at day 0  with Mt/IFA.  Polyclonal lymph node 
responses  were measured at day 10. 
mune models. In the present report we have described the 
design of such competitor peptides based on two disease- 
associated Lewis rat T cell epitopes: the 180-188 T cell epi- 
tope of the mycobacterial 65-kD heat-shock protein,  which 
appeared to be critical in AA and which was recognized by 
the arthritogenic T cell clone A2b, and the 72-85 T cell epi- 
tope of guinea pig MBP recognized by the encephalitogenic 
T  cell line Zla. Both Zla and A2b were restricted by the 
MHC  class II  RT1  B  L locus products  (25). First,  single 
16 
C 
Z  2. 
12  14  16  19  21  23  26  28  30  36  42 
Days  after  ivlt  ~rnmuntzat~on 
I  OOA/mB$  -- e  --  DOAIA 183 
/IFA  Mt  IIFA 
Figure 6.  Inhibition of adjuvant arthritis by preimmunization with pep- 
tide A183. Rats were immunized at day - 7 with PBS/DDA (control group 
n  =  4) or with 50 #g peptide A183 DDA (A183 group, n  =  4) and at 
day 0 with Mt/IFA. Rats were followed  for disease development from 
day  11 after immunization until day 43. The results shown are from a 
representative experiment and expressed as the mean arthritis score of each 
group.  SE is indicated by a bar. 
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to define nonstimulatory analogues (Hg. 1, A and B). These 
nonstimulatory analogue peptides  were tested in competi- 
tion assays in vitro to study their capacity to inhibit antigen- 
induced proliferation  of done A2b and Zla. In contrast to 
most previous studies (4, 5, 8), these competition assays were 
performed with nonfixed viable APCs to approach the in vivo 
situation as well as possible. The AA-associated peptide ana- 
logue of 180-188, peptide A183, showed, compared with the 
EAE-associated analogue 1028, a stronger inhibition of the 
antigen-induced proliferation of T cell clone A2b (Fig 3 A). 
However, the response of T cell line Zla was inhibited most 
effidently by the EAE-associated analogue peptide 1028 (Fig. 
3 B). Because this functional inhibition assay is a rather in- 
direct method to measure competition for MHC binding, 
we also performed direct MHC-peptide binding assays on 
isolated MHC molecules to define the MHC binding affinity 
of both  competitor peptides.  It  appeared  that  the EAE- 
associated competitor peptide 1028 had a higher MHC binding 
aftinity as compared with the AA-associated competitor pep- 
tide A183 (Fig. 4, A and B). Therefore, it could well be pos- 
sible that  the stronger inhibition of the  antigen-induced 
proliferation  of clone A2b by the AA-associated competitor 
A183 resulted not only from a successful competition with 
the stimulatory antigen at the level of MHC binding, but 
that alternative antigen-specific mechanisms were involved. 
These mechanisms may include the induction of anergy (34), 
in which the inhibitor peptide induces T cell tolerance, or 
the very recently described antigen-specific  mechanism of TCR 
antagonism (35), in which the TCR becomes occupied by 
the analogue peptide-MHC complex without any signal trans- 
duction. 
In the in vivo experiments addition of the AA-associated 
competitor peptide A183 to the EAE-inducing preparation 
of peptide 1020 (MBP 72-85)/CFA resulted in a strong inhi- 
bition of EAE, while addition of the EAE-associated com- 
petitor 1028 completely inhibited EAE development  (Table 
1). In the animals coimmunized with the competitor pep- 
tides during EAE induction, polyclonal lymph node responses 
against the encephalitogenic peptide 1020 were found to be 
inhibited (Table 2). These data demonstrated that not only 
the disease-associated competitor peptide 1028 but also the 
AA-associated peptide A183 was capable of inhibiting EAE 
induction by in vivo competitive inhibition of the priming 
of a T cell response against the encephalitogenic peptide 1020. 
This was in accordance with the data of Lamont et al. (36), 
which also showed in the mouse that a fully unrelated pep- 
tide was inhibitory to peptide-induced EAE. 
In contrast to the findings in the EAE model, in the more 
complex AA model only coimmunization of the AA-associated 
competitor peptide A183 resulted in a significant disease  reduc- 
tion (p <  0.001), while the stronger MHC binding EAE- 
associated peptide 1028 did not. Because of the failure of pep- 
tide 1028 to interfere in the AA model, it is not likely that 
the disease induction by addition of peptide A183 was only 
inhibited by competition for MHC binding. A possible clue 
for the mechanism that could be relevant for the dramatic 
in vivo AA-suppressing  activity of the AA-associated pep- 
tide A183 was obtained by the observation of unexpected T 
cell responsiveness after administration ofpeptide A183 during 
AA induction. In rats protected from AA by coimmuniza- 
tion with peptide A183, in addition to responses to peptide 
A183, increased responses against the native peptide 180-188 
were seen, while responses against the mycobacterial 65-kD 
protein or Mt were not affected (Table 4).  Although the 
180-188 epitope of the mycobacterial 65-kD protein has been 
described as an important AA-associated epitope (23), at the 
polyclonal level, responses against this epitope were often hard 
to detect and normally not present at day 43 after Mt immu- 
nization, while responses against Mt or the 65-kD protein 
were very obvious (37). Therefore, in all other experimental 
groups, coimmunized with Mt together with PBS, the EAE- 
associated competitor 1028, or with the control peptides, no 
responses against peptide 180-188 were detected at day 43 
after immunization (Table 4). However, be that as it may, 
coimmunization ofpeptide A183 together with Mt resulted 
in both disease reduction and triggering of T cell responses 
against peptide A183 and the original disease-associated pep- 
tide 180-188.  From the polydonal lymph node responses, 
however, it could not be conduded that the same T cells rec- 
ognized both peptides A183 and 180-188, or that different 
T cell populations responded to the different peptides.  For 
that reason we generated a T ceU clone against peptide A183 
and revealed that these T cells indeed recognized not only 
peptide A183, but also the original peptide 180-188 (Table 5). 
In support of our hypothesis, that peptide A183 did inter- 
fete in the AA model not only by MHC blockade but in 
addition by antigen-specific immunomodulatory mechanisms, 
were also our findings that even rats preimmunized with pep- 
tide A183 7 d before AA induction featured reduced disease 
(Fig. 6) whereas, in the EAE model, in which the disease 
was induced with the encephalitogenic peptide 1020/CFA, 
no effect of such pretreatment with peptide A183 was ob- 
served. Arthritis inhibition was, in this situation, probably 
not due to MHC blocking by residual peptide A183, because 
a relative low dose (50/~g) was used compared with the coim- 
munization experiments  (250-500/~g),  and because in the 
peptide-induced EAE no inhibitory effect was seen. The exact 
mechanisms of the antigen-specific immunomodulatory qual- 
ities of peptide A183 in the AA model, however, remain to 
be elucidated. The strong in vitro inhibition by peptide A183 
on the peptide 180-188-induced proliferation of the arthrito- 
genic T  cell done A2b suggests that the TCR antagonist 
mechanism (35) could play an important role. However, such 
a T ceLl  antagonist mechanism fails to explain the preimmu- 
nization experiments in vivo in which AA was inhibited by 
a relatively low dose of peptide A183 injected 1 wk before 
disease induction. Furthermore, in the in vitro experiments 
we have obtained additional experimental support for an ac- 
tive immunoregulatory mechanism of peptide A183 inter- 
ference in the AA model. In the AA model it has already 
been demonstrated that immunization with attenuated ar- 
thritogenic A2b ceils induced protection by triggering disease- 
specific regulatory T cells (38). Furthermore, Offner et al. 
675  Wauben et al. (39) recently demonstrated that T cells recognizing different 
MBP epitopes can induce a crossreactive immunity against 
a TCR idiotope that  is shared by these cells.  Therefore, it 
is possible that the T cells recognizing both the competitor 
peptide A183 and the original peptide 180-188, and which 
we have shown to become activated in our in vivo immuni- 
zation experiments with peptide A183, play a crucial role. 
Because of the close relationship of such cells with the disease- 
inducing 180-188-specific T cells not only at the level of an- 
tigen specificity but possibly also at the TCR level, they may 
induce  regulatory  antiidiotypic  responses  directed  against 
shared TCR idiotopes, thereby preventing the development 
of AA. However, alternative explanations such as that pep- 
tide A183 induces anergy in the arthritogenic 180-188-specific 
T  cell population or the specific triggering of other regula- 
tory suppressive mechanisms  are not  to be excluded. 
Irrespective of the actual mechanism, the disease-suppressive 
properties of such novel competitor-moduhtor peptides would 
make them attractive devices for the treatment of human au- 
toimmune diseases, where we may have to deal with antigens 
of a relatively complex nature. In that situation we may need 
peptides harboring activities exceeding MHC blocking alone. 
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